Blood pressure measurement at kiosks in public spaces: systematic review and consensus statement by the European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability endorsed by the International Society of Hypertension and the World Hypertension League

: Stergiou, George S.; Kyriakoulis, Konstantinos G.; Kollias, Anastasios; Mcmanus, Richard J.; Menti, Ariadni; Parati, Gianfranco; Schutte, Aletta E.; Wang, Jiguang; Asayama, Kei; Asmar, Roland; Bilo, Grzegorz; Chapman, Niamh; Fujiwara, Takeshi; Head, Geoffrey; Kahn, Nadia; Kario, Kazuomi; Li, Yan; Manios, Efstathios; Mariglis, Dimitrios; Mihailidou, Anastasia S.; Muntner, Paul; Myers, Martin; Niiranen, Teemu; Ohkubo, Takayoshi; Omboni, Stefano; Protogerou, Athanasios; Saladini, Francesca; Sharman, James; Shimbo, Daichi; de la Sierra, Alejandro; Palatini, Paolo

Publisher: Ovid Technologies (Wolters Kluwer Health)

: PHILADELPHIA

: 2025

: Journal of Hypertension

: J HYPERTENS

: 43

: 4

: 577

: 588

: 12

: 0263-6352

: 1473-5598

DOI: https://doi.org/10.1097/HJH.0000000000003965

: https://doi.org/10.1097/hjh.0000000000003965

Kiosk devices for unsupervised self-measurement of blood pressure (BP) are being used in public spaces and healthcare settings in several countries. This statement by the European Society of Hypertension (ESH) Working Group on BP Monitoring and Cardiovascular Variability provides a review of the published evidence on kiosk BP devices and consensus recommendations for their requirements and clinical use. A systematic literature search identified 54 relevant studies. Kiosk BP measurements appeared to be close to office BP [mean difference systolic 0.2 mmHg (95% confidence intervals -1.3 to 1.8); diastolic -0.4 mmHg (-3.5 to 2.7)], and higher than daytime ambulatory and home BP [mean difference 6.0 mmHg (1.6-10.4)/5.0 (2-8) and 8.1 mmHg (-2.6 to 18.9)/0.2 (-9.6 to 10.0), respectively]. Randomized or observational studies using kiosk BP measurements for hypertension screening or for assessing hypertension control were also included, as well as studies investigating users' and healthcare professionals' opinions, acceptability, and perspectives regarding kiosk BP measurements, and validation studies of kiosk BP devices. These studies had considerable heterogeneity in design, setting, methodology, measurement protocol, and sample size. Thus, at present, the clinical utility of kiosk BP measurements is uncertain. This ESH consensus statement acknowledges the potential of kiosk BP measurement as an emerging method for unsupervised self-measurement in the context of opportunistic screening for hypertension in apparently healthy people and the long-term monitoring of people with diagnosed hypertension. Requirements for the design, validation, function, and use of kiosk BP monitors are provided, together with the pending research questions on their optimal implementation in clinical practice.

:
G.S.S. conducted clinical development and validation studies for various manufacturers of blood pressure measurement technologies and advised manufacturers on device and software development. K.G.K., A.K., A.M., and D.M. contributed to validation studies of blood pressure devices with payments made to the Athens University Special Account for Research Grants. R.J.M. worked with Omron to develop a telemonitoring solution for which the University of Oxford received consultancy and licensing payments. G.P. received honoraria for lectures by Omron Health Care, Merck, Viatris. A.E.S. received financial support from Omron, Sky Labs, Aktiia, Medtronic, Servier, AstraZeneca, Sanofi, Abbott, Novartis. J.W. received research funding for validation of blood pressure monitors from Contec, Huawei, Omron. K.A. worked as a consultant for blood pressure device manufacturers. R.A. worked as a consultant for blood pressure device manufacturers and participated in sponsored studies to validate blood pressure measurement devices. K.K. received research grants from Omron Healthcare A&D and Fukuda Denshi. Y.L. received research grants and lecture fees from A&D and Omron. P.M. worked as a scientific advisor to Skylabs Inc and owner of Perisphere Real World Evidence, LLC. T.O. received lecture fees and a joint research grant from Omron Healthcare. P.P. provided validation studies for several manufacturers (Hingmed, InBody, Microlife). None for the other authors.